Study on Safety and Tolerance of TCK-276 for Rheumatoid Arthritis

Study Description

This study aims to assess the safety, tolerance, and pharmacokinetics of TCK-276, an oral medicine, in patients with rheumatoid arthritis. The study is a phase 1, randomized, double-blind, and placebo-controlled trial. It will consist of a screening visit, treatment duration, and a follow-up/end of treatment visit. There will be four cohorts, and each will receive an oral dose of TCK-276 or matching placebo for seven days under fed conditions. The study duration is around 42 days. The trial will help determine the safety and tolerability of TCK-276 for the treatment of rheumatoid arthritis.

Study Details

Registry ID:

NCT05437419

Conditions:

Rheumatoid Arthritis

Phase:

Phase 1

Target Enrollment:

32 participants

Start Date:

August 10, 2022

Age Range:

18–64 years

Healthy Volunteers:

No

Study Locations (10 sites)

• SouthCoast Research Center, Inc
  Miami, FloridaUnited States, United States
• Allied Biomedical Research Institute
  Miami, FloridaUnited States, United States
• San Marcus Research Clinic, Inc.
  Miami Lakes, FloridaUnited States, United States
• Floridian Clinical Research, LLC
  Miami Lakes, FloridaUnited States, United States
• St Jude Clinical Research, LLC
  Doral, FloridaUnited States, United States
• St. Jude Clinical Research, LLC
  Doral, FloridaUnited States, United States
• Clinical Site Partners, LLC dba CSP Orlando
  Winter Park, FloridaUnited States, United States
• SMS Clinical Research
  Mesquite, TexasUnited States, United States
• SMS Clinical Research, LLC
  Mesquite, TexasUnited States, United States
• Orange County Research Center
  Tustin, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →